Cytokinetics Highlights Q4 Earnings and MYQORZO Launch

Biotech firm reports progress on new heart disease drug, pipeline, and 2026 expense guidance.

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

Cytokinetics used its Q4 2025 earnings call to highlight the FDA approval and initial U.S. launch of its new drug MYQORZO for adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The company also provided updates on advancing late-stage clinical programs and 2026 expense guidance.

Why it matters

The approval and launch of MYQORZO represents a major transition for Cytokinetics as it moves from a clinical-stage biotech to a commercial-stage company. The drug's success will be crucial for the firm's future growth and ability to invest in its pipeline of muscle biology-focused therapies for cardiac and skeletal muscle diseases.

The details

Cytokinetics highlighted several positive early indicators for the MYQORZO launch, including rapid healthcare provider certification, patient enrollment in support programs, and the first prescriptions being dispensed within days of availability. The company plans to report key launch metrics starting in Q1 2026, with a goal of achieving over 50% new patient preference share in the cardiac myosin inhibitor category by the end of 2026. Cytokinetics also has several late-stage pipeline programs advancing, including a supplemental NDA submission for MYQORZO and the ACACIA-HCM pivotal Phase 3 trial of aficamten in non-obstructive HCM.

  • Cytokinetics received FDA approval for MYQORZO in December 2025.
  • MYQORZO became available to patients in late January 2026.
  • Cytokinetics plans to report Q1 2026 launch metrics starting in its next earnings call.
  • The company expects a potential FDA decision on the MAPLE-HCM supplemental NDA by Q4 2026.
  • Top-line results from the ACACIA-HCM Phase 3 trial are expected in Q2 2026.

The players

Cytokinetics

A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function, including for cardiac and skeletal muscle diseases.

Robert Blum

President and CEO of Cytokinetics.

Andrew Callos

Executive Vice President and Chief Commercial Officer of Cytokinetics.

Stuart Kupfer

Senior Vice President and Chief Medical Officer of Cytokinetics.

Fady Malik

Executive Vice President of Research and Development at Cytokinetics.

Got photos? Submit your photos here. ›

What they’re saying

“The fourth quarter represented a 'defining moment' for Cytokinetics following the FDA approval of MYQORZO in December for symptomatic obstructive HCM.”

— Robert Blum, President and CEO (themarketsdaily.com)

“Certification consists of a self-study training and a scored 10-question assessment that generally takes 10–20 minutes, adding that it has 'really not been a barrier.'”

— Andrew Callos, Executive Vice President and Chief Commercial Officer (themarketsdaily.com)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Cytokinetics' approval and launch of MYQORZO represents a major milestone for the company as it transitions to a commercial-stage biotech. The early indicators for the drug's launch are encouraging, but Cytokinetics will need to continue executing well to achieve its goal of over 50% new patient preference share in the cardiac myosin inhibitor category by the end of 2026 while also advancing its promising pipeline of muscle biology-focused therapies.